» Articles » PMID: 9744306

Tissue-specific Expression Pattern of Vascular Endothelial Growth Factor Isoforms in the Malignant Transformation of Lung and Colon

Overview
Journal Hum Pathol
Specialty Pathology
Date 1998 Sep 23
PMID 9744306
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Angiogenesis, a prerequisite for tumor growth and progression, results from a shift in the equilibrium between angiogenic factors and angiogenic inhibitors. Vascular endothelial growth factor (VEGF) has been identified as one of the most important factors mediating angiogenesis in physiological and pathological conditions. Through alternative splicing, four isoforms of VEGF are formed, consisting of 206, 189, 165, and 121 amino acids, respectively. VEGF206 and VEGF189 differ from VEGF165 and VEGF121 in their bioavailability, with the longer forms being matrix-bound and the shorter forms freely diffusible. To investigate the relative importance of the VEGF isoforms in neoplastic transformation, we studied the pattern of splice variant expression by reverse transcription polymerase chain reaction (RT-PCR) in 18 lung and 11 colonic carcinomas and their corresponding normal tissues, respectively. The findings showed a significant upregulation of VEGF in both carcinomas, with VEGF165 and VEGF121 being the predominant forms; VEGF189 was significantly expressed in normal lung but not colon; and VEGF206 was not detected in any specimen. The findings indicate that during malignant progression, an angiogenic switch favoring the shorter diffusible isoforms is likely to confer on the tumor a growth advantage. From the differential expression of VEGF isoforms in normal lung and colonic tissues, different functional roles of the splice variants is suggested. In particular, VEGF189 may be important for the maintenance of the vascular integrity of the lung.

Citing Articles

Predictive Value of Circulatory Total VEGF-A and VEGF-A Isoforms for the Efficacy of Anti-PD-1/PD-L1 Antibodies in Patients with Non-Small-Cell Lung Cancer.

Hirakawa T, Yamaguchi K, Funaishi K, Shimoji K, Sakamoto S, Horimasu Y Cancers (Basel). 2025; 17(4).

PMID: 40002167 PMC: 11853576. DOI: 10.3390/cancers17040572.


How VEGF-A and its splice variants affect breast cancer development - clinical implications.

Al Kawas H, Saaid I, Jank P, Westhoff C, Denkert C, Pross T Cell Oncol (Dordr). 2022; 45(2):227-239.

PMID: 35303290 PMC: 9050780. DOI: 10.1007/s13402-022-00665-w.


Evaluation of recombinant human vascular endothelial growth factor VEGF121-loaded poly-l-lactide microparticles as a controlled release delivery system.

Abraham S, Rangaswamy S, Chinnaiah A Turk J Biol. 2020; 44(1):34-47.

PMID: 32123494 PMC: 7049456. DOI: 10.3906/biy-1908-32.


Altered VEGF Splicing Isoform Balance in Tumor Endothelium Involves Activation of Splicing Factors Srpk1 and Srsf1 by the Wilms' Tumor Suppressor Wt1.

Wagner K, El Mai M, Ladomery M, Belali T, Leccia N, Michiels J Cells. 2019; 8(1).

PMID: 30641926 PMC: 6356959. DOI: 10.3390/cells8010041.


Expression, purification and functionality of bioactive recombinant human vascular endothelial growth factor VEGF in E. coli.

Taktak-BenAmar A, Morjen M, Mabrouk H, Abdelmaksoud-Dammak R, Guerfali M, Fourati-Masmoudi N AMB Express. 2017; 7(1):33.

PMID: 28168572 PMC: 5293700. DOI: 10.1186/s13568-016-0300-2.